vs

Side-by-side financial comparison of Fortress Biotech, Inc. (FBIO) and VALUE LINE INC (VALU). Click either name above to swap in a different company.

Fortress Biotech, Inc. is the larger business by last-quarter revenue ($16.1M vs $8.3M, roughly 1.9× VALUE LINE INC). VALUE LINE INC runs the higher net margin — 71.4% vs -24.5%, a 95.9% gap on every dollar of revenue. On growth, Fortress Biotech, Inc. posted the faster year-over-year revenue change (6.3% vs -7.7%). Over the past eight quarters, Fortress Biotech, Inc.'s revenue compounded faster (11.0% CAGR vs -4.1%).

Fortress Biotech Inc., commonly known as Fortress Bio, is a biopharmaceutical company that acquires, develops, and commercializes innovative pharmaceutical and biotechnology products. Led by CEO Lindsay A. Rosenwald, M.D., Fortress and most of its subsidiary companies are headquartered in Bay Harbor Islands, Florida.

Value Line, Inc. is a publicly traded investment research and financial publishing firm based in New York City. Founded in 1931 by Arnold Bernhard, Value Line is best known for publishing The Value Line Investment Survey, a stock analysis newsletter that tracks approximately 1,700 publicly traded stocks.

FBIO vs VALU — Head-to-Head

Bigger by revenue
FBIO
FBIO
1.9× larger
FBIO
$16.1M
$8.3M
VALU
Growing faster (revenue YoY)
FBIO
FBIO
+14.0% gap
FBIO
6.3%
-7.7%
VALU
Higher net margin
VALU
VALU
95.9% more per $
VALU
71.4%
-24.5%
FBIO
Faster 2-yr revenue CAGR
FBIO
FBIO
Annualised
FBIO
11.0%
-4.1%
VALU

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
FBIO
FBIO
VALU
VALU
Revenue
$16.1M
$8.3M
Net Profit
$-3.9M
$5.9M
Gross Margin
66.1%
Operating Margin
-28.8%
12.1%
Net Margin
-24.5%
71.4%
Revenue YoY
6.3%
-7.7%
Net Profit YoY
41.8%
14.5%
EPS (diluted)
$-0.15

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FBIO
FBIO
VALU
VALU
Q1 26
$8.3M
Q4 25
$16.1M
$8.6M
Q3 25
$17.6M
$8.6M
Q2 25
$16.4M
$8.4M
Q1 25
$13.1M
$9.0M
Q4 24
$15.1M
$8.8M
Q3 24
$14.6M
$8.9M
Q2 24
$14.9M
$9.0M
Net Profit
FBIO
FBIO
VALU
VALU
Q1 26
$5.9M
Q4 25
$-3.9M
$5.7M
Q3 25
$5.8M
$6.5M
Q2 25
$15.5M
$4.0M
Q1 25
$-10.6M
$5.2M
Q4 24
$-6.8M
$5.7M
Q3 24
$-12.9M
$5.9M
Q2 24
$-10.9M
$4.8M
Gross Margin
FBIO
FBIO
VALU
VALU
Q1 26
Q4 25
66.1%
Q3 25
67.4%
Q2 25
69.9%
Q1 25
63.5%
Q4 24
69.1%
Q3 24
69.4%
Q2 24
61.6%
Operating Margin
FBIO
FBIO
VALU
VALU
Q1 26
12.1%
Q4 25
-28.8%
17.7%
Q3 25
-38.6%
17.4%
Q2 25
-222.2%
9.9%
Q1 25
-169.9%
17.4%
Q4 24
-158.3%
19.7%
Q3 24
-151.0%
20.8%
Q2 24
-186.5%
16.5%
Net Margin
FBIO
FBIO
VALU
VALU
Q1 26
71.4%
Q4 25
-24.5%
66.4%
Q3 25
33.2%
75.1%
Q2 25
94.4%
47.1%
Q1 25
-80.6%
57.6%
Q4 24
-44.7%
64.3%
Q3 24
-88.0%
66.3%
Q2 24
-73.5%
53.1%
EPS (diluted)
FBIO
FBIO
VALU
VALU
Q1 26
Q4 25
$-0.15
Q3 25
$0.11
Q2 25
$0.45
Q1 25
$-0.48
Q4 24
$-0.16
Q3 24
$-0.76
Q2 24
$-0.73

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FBIO
FBIO
VALU
VALU
Cash + ST InvestmentsLiquidity on hand
$79.4M
$92.5M
Total DebtLower is stronger
$52.4M
Stockholders' EquityBook value
$49.9M
$107.8M
Total Assets
$185.5M
$151.0M
Debt / EquityLower = less leverage
1.05×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FBIO
FBIO
VALU
VALU
Q1 26
$92.5M
Q4 25
$79.4M
$86.6M
Q3 25
$86.2M
$33.7M
Q2 25
$74.4M
$67.7M
Q1 25
$91.3M
$52.8M
Q4 24
$57.3M
$22.3M
Q3 24
$58.9M
$30.9M
Q2 24
$76.2M
$4.4M
Total Debt
FBIO
FBIO
VALU
VALU
Q1 26
Q4 25
$52.4M
Q3 25
$47.8M
Q2 25
$50.0M
Q1 25
$56.4M
Q4 24
$58.0M
Q3 24
$52.5M
Q2 24
$67.0M
Stockholders' Equity
FBIO
FBIO
VALU
VALU
Q1 26
$107.8M
Q4 25
$49.9M
$105.5M
Q3 25
$55.9M
$103.0M
Q2 25
$43.9M
$99.7M
Q1 25
$22.3M
$99.0M
Q4 24
$22.7M
$96.7M
Q3 24
$21.2M
$93.9M
Q2 24
$17.9M
$90.8M
Total Assets
FBIO
FBIO
VALU
VALU
Q1 26
$151.0M
Q4 25
$185.5M
$147.9M
Q3 25
$181.4M
$148.2M
Q2 25
$159.9M
$144.5M
Q1 25
$178.1M
$143.6M
Q4 24
$144.2M
$140.0M
Q3 24
$127.1M
$138.6M
Q2 24
$145.7M
$136.0M
Debt / Equity
FBIO
FBIO
VALU
VALU
Q1 26
Q4 25
1.05×
Q3 25
0.86×
Q2 25
1.14×
Q1 25
2.53×
Q4 24
2.55×
Q3 24
2.48×
Q2 24
3.75×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FBIO
FBIO
VALU
VALU
Operating Cash FlowLast quarter
$-12.5M
$5.3M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
0.89×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FBIO
FBIO
VALU
VALU
Q1 26
$5.3M
Q4 25
$-12.5M
$3.0M
Q3 25
$-6.1M
$5.6M
Q2 25
$-27.6M
$20.2M
Q1 25
$-19.6M
$6.9M
Q4 24
$-12.9M
$3.1M
Q3 24
$-20.1M
$4.8M
Q2 24
$-21.8M
$17.9M
Free Cash Flow
FBIO
FBIO
VALU
VALU
Q1 26
Q4 25
Q3 25
Q2 25
$20.1M
Q1 25
$6.8M
Q4 24
$3.0M
Q3 24
$4.8M
Q2 24
$17.9M
FCF Margin
FBIO
FBIO
VALU
VALU
Q1 26
Q4 25
Q3 25
Q2 25
239.2%
Q1 25
75.3%
Q4 24
34.1%
Q3 24
53.7%
Q2 24
199.0%
Capex Intensity
FBIO
FBIO
VALU
VALU
Q1 26
0.0%
Q4 25
0.0%
Q3 25
0.0%
Q2 25
2.1%
Q1 25
1.2%
Q4 24
0.7%
Q3 24
0.0%
0.0%
Q2 24
0.2%
Cash Conversion
FBIO
FBIO
VALU
VALU
Q1 26
0.89×
Q4 25
0.52×
Q3 25
-1.04×
0.86×
Q2 25
-1.78×
5.12×
Q1 25
1.33×
Q4 24
0.54×
Q3 24
0.81×
Q2 24
3.75×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons